Tetrahedron-near-infrared quantum dot probe with tumor targeting property as well as preparation method and application of tetrahedron-near-infrared quantum dot probe

By combining DNA tetrahedron with near-infrared quantum dots and introducing tumor-targeting molecules, a tetrahedron-near-infrared quantum dot probe with tumor targeting is solved, and the tumor targeting deficiency and photobleaching in the prior art are solved. Problem, achieving efficient imaging and early diagnosis of deep tumors.

CN118949078APending Publication Date: 2024-11-15XIANGFU LABORATORY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411033401.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing near-infrared fluorescent tetrahedral probes are insufficient in tumor targeting and fluorescent dyes are prone to photobleaching, making it impossible to achieve long-term and deep-tissue tumor imaging.

Method used

By combining DNA tetrahedron with near-infrared quantum dots and introducing tumor-specific targeting molecules through chemical coupling reactions, a tetrahedron-near-infrared quantum dot probe with tumor targeting is formed, and the hydrophobic space of DNA tetrahedron is used. The cavity encapsulates quantum dots and modifys targeting molecules on the surface.

Benefits of technology

It realizes high-efficiency imaging and long-term tracking of deep tumors, provides good biosafety, high fluorescence quantum yield and high imaging brightness, and is suitable for early diagnosis and treatment monitoring of deep tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949078A_ABST
    Figure CN118949078A_ABST
Patent Text Reader

Abstract

The invention provides a tetrahedron-near-infrared quantum dot probe with tumor targeting and a preparation method and application thereof. The preparation method comprises the following steps: 1) preparing a DNA tetrahedron nanostructure with a hydrophobic cavity; 2) providing a hydrophobic quantum dot with a near-infrared luminescence property; 3) performing oscillation or ultrasonic mixing on the DNA tetrahedron and the hydrophobic quantum dot to prepare a tetrahedron-near-infrared quantum dot probe; and 4) covalently binding tumor specific targeting molecules to the surface of the tetrahedron-near-infrared quantum dot probe through a chemical coupling reaction, so as to prepare the tetrahedron-near-infrared quantum dot probe with tumor targeting property. The near-infrared quantum dot fluorescent tetrahedron probe prepared by the method has good biological safety, high fluorescence quantum yield, high imaging brightness, good tumor targeting and deep tumor tissue imaging capability, and has good medical application prospects in early diagnosis of deep tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and more specifically to a tetrahedron-near infrared quantum dot probe with tumor targeting, a preparation method thereof, and an application thereof in deep tissue tumor imaging. Background Art

[0002] Early diagnosis and monitoring of deep tissue tumors are crucial to improve the success rate of cancer treatment. However, existing imaging technologies such as X-ray, CT and MRI have certain limitations in detecting tiny tumors and real-time monitoring. Near-infrared (NIR) quantum dots have become a very promising bioimaging probe due to their superior optical properties, such as high fluorescence quantum yield, good photostability and deep tissue penetration. However, the biocompatibility and targeting of quantum dots still need to be further optimized.

[0003] The development of DNA nanotechnology has provided a new way to construct nanostructures with specific morphology and functions. DNA tetrahedron is a nanostructure formed by self-assembly of single DNA strands, which has high symmetry and stability. DNA tetrahedron not only has good biocompatibility and biodegradability, but also has a specific geometric morphology, which can provide abundant surface modification sites for binding various functional molecules.

[0004] In the inventor's previous research (see Chinese patent application "CN202311066360.7"), a near-infrared fluorescent tetrahedron probe and its preparation method and application were developed to achieve tumor imaging close to the single-cell level. However, in this method, the designed probe has insufficient tumor targeting, and the fluorescent dye is prone to photobleaching, which makes it impossible to achieve long-term imaging tracking. Therefore, there are still certain challenges in practical applications. Summary of the invention

[0005] The purpose of the present invention is to provide a tetrahedron-near infrared quantum dot probe with tumor targeting, a preparation method thereof, and an application in deep tissue tumor imaging, so as to solve the problem that the near-infrared fluorescent tetrahedron probe in the prior art has insufficient tumor targeting and the problem that deep tissue tumor imaging cannot be achieved due to the easy photobleaching of fluorescent dyes.

[0006] In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0007] According to a first aspect of the present invention, a method for preparing a tetrahedron-near-infrared quantum dot probe with tumor targeting is provided, comprising the following steps: 1) four DNA single strands are modified with hydrophobic alkyl chains respectively, and a DNA tetrahedron nanostructure with a hydrophobic cavity is prepared through a thermal annealing process; 2) a hydrophobic quantum dot with near-infrared luminescence properties is provided; 3) the DNA tetrahedron and the hydrophobic quantum dot are mixed by oscillation or ultrasound, so that the hydrophobic quantum dot enters the hydrophobic cavity of the DNA tetrahedron, thereby preparing a tetrahedron-near-infrared quantum dot probe; and 4) a tumor-specific targeting molecule is covalently bonded to the surface of the tetrahedron-near-infrared quantum dot probe through a chemical coupling reaction, thereby preparing a tetrahedron-near-infrared quantum dot probe with tumor targeting.

[0008] In step 1), the DNA tetrahedron is composed of four single-stranded DNAs with specific sequences, with hydrophobic alkyl chains modified at the ends of the sequences, to form a DNA tetrahedron structure through self-assembly. Each single-stranded DNA has a complementary sequence and can spontaneously form a highly stable tetrahedron structure with a hydrophobic cavity through an annealing process under appropriate conditions.

[0009] Preferably, in step 1), the side length of the DNA tetrahedron structure composed of four single-stranded DNAs is 20 base pairs and the size is about 6.8 nanometers.

[0010] Preferably, in step 2), the hydrophobic quantum dots having near-infrared luminescence properties include: CdTe, PbS, PbSe, Ag2S quantum dots, etc.

[0011] Preferably, in step 2), the size of the hydrophobic quantum dots having near-infrared luminescence properties cannot exceed 5 nanometers.

[0012] According to a preferred embodiment of the present invention, in step 3), the hydrophobic quantum dots with near-infrared luminescent properties and DNA tetrahedrons are mixed in a molar ratio of (80-120):1 and then sonicated for 5 minutes, so that the hydrophobic quantum dots can enter the hydrophobic cavity of the DNA tetrahedron by utilizing hydrophilic-hydrophobic interaction, and agarose gel electrophoresis is used to verify whether the quantum dots are successfully encapsulated.

[0013] More preferably, the near-infrared luminescent hydrophobic quantum dots and the DNA tetrahedrons are mixed at a molar ratio of 100:1.

[0014] In step 4), the tetrahedron-near infrared quantum dot probe can covalently bind tumor-specific targeting molecules to the surface of the DNA tetrahedron through a chemical coupling reaction (such as EDC / NHS activation). These targeting molecules can recognize and bind to specific receptors on tumor cells to achieve efficient targeting of the probe. For example, antibodies (Herceptin targets human epidermal growth factor receptor 2, Rituximab targets CD20 antigen, Cetuximab targets epidermal growth factor receptor, Bevacizumab targets vascular endothelial growth factor), peptides (RGD peptide targets integrin αvβ3 / β5, Bombesin peptide targets gastrin-releasing peptide receptor, Folate peptide targets folate receptor), small molecules (folic acid, glucose), etc.

[0015] Preferably, integrins αvβ3 and αvβ5 are expressed in various types of tumors, including breast cancer, prostate cancer, lung cancer, liver cancer, brain tumors, etc. Therefore, RGD polypeptides can be used for targeted therapy and imaging of various cancers and have wide applicability.

[0016] According to the second aspect of the present invention, a tetrahedron-near-infrared quantum dot probe prepared according to the above-mentioned preparation method is provided. The tetrahedron-near-infrared quantum dot probe uses a DNA tetrahedron with a hydrophobic cavity to encapsulate quantum dots with near-infrared luminescent properties through hydrophilic-hydrophobic interactions, and is covalently bound to tumor-specific targeting molecules through a chemical coupling reaction.

[0017] The present invention can give full play to the advantages of both by combining DNA tetrahedrons with near-infrared quantum dots. DNA tetrahedrons can be used as carriers and protective shells for quantum dots to improve the stability and dispersibility of quantum dots in vivo. At the same time, the surface of DNA tetrahedrons is easy to modify, and tumor targeting molecules can be introduced through simple chemical reactions to enhance the targeting and imaging sensitivity of quantum dot probes. Such a design can not only achieve efficient imaging of deep tumors, but also provide more information for early diagnosis and treatment monitoring of tumors. Therefore, the tetrahedron-near-infrared quantum dot probe prepared according to the present invention not only has good deep tissue penetration ability, but also has good tumor targeting, and can be used for imaging of deep tumor tissues.

[0018] According to a third aspect of the present invention, there is provided an application of a tetrahedron-near infrared quantum dot probe in deep tissue tumor imaging, wherein the tumor imaging includes: imaging of tumors such as lung cancer, colorectal cancer, and liver cancer.

[0019] According to a preferred embodiment of the present invention, the application includes the following steps: S1: construction of an in situ liver cancer mouse model; S2: covalently modifying the RGD polypeptide on the tetrahedron-near-infrared quantum dot probe to obtain a tetrahedron-near-infrared quantum dot probe with the ability to actively target tumors; S3: injecting 1 μM tetrahedron-near-infrared quantum dot probe into the tail vein, and after the mouse is anesthetized and immobilized, near-infrared mouse live imaging is performed under 808 nm laser irradiation.

[0020] The key invention of the present invention is that a tetrahedron-near-infrared quantum dot probe is provided for the first time. The advantages of quantum dots over small molecule dyes are that, firstly, quantum dots in the near-infrared wavelength range have lower scattering and absorption in biological tissues, and therefore can penetrate tissues more deeply. Although infrared fluorescent dyes also emit light in the near-infrared region, their usual emission wavelength range and photon scattering properties are not as ideal as those of quantum dots. Secondly, quantum dots have high photostability and can maintain long-term luminescence, which is suitable for long-term imaging and deep imaging, while fluorescent dyes are prone to photobleaching. Therefore, the tetrahedron-near-infrared quantum dot probe provided by the present invention is more suitable for imaging deep tumor tissues.

[0021] Another key invention of the present invention is that tumor-specific targeting molecules are covalently bound to the surface of tetrahedron-near-infrared quantum dot probes through a chemical coupling reaction. These tumor-specific targeting molecules can recognize and bind to specific receptors on tumor cells, thereby achieving efficient targeting of the probe. By injecting the probe into the tail vein, the probe can actively target the tumor site for imaging. Therefore, the present invention has good clinical translation significance.

[0022] The effect of the present invention relative to the existing technological progress is that the tetrahedron-near infrared quantum dot probe provided by the present invention has good biosafety, high fluorescence quantum yield, high imaging brightness, good tumor targeting and deep tumor tissue imaging capabilities in deep tumor imaging, so the probe can be well applied to in vivo tumor imaging, can solve the problem of deep tumor tissue being difficult to detect, and has good medical application prospects for early diagnosis of deep tumors. The present invention also further improves its performance in deep tissue tumor imaging by optimizing the preparation method of the probe, providing a powerful tool for early diagnosis and treatment of tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 It is a schematic diagram of the preparation process of a tetrahedron-near infrared quantum dot probe;

[0024] Figure 2 The agarose electrophoresis diagram of the tetrahedron-near infrared quantum dot probe prepared in Example 1 is shown;

[0025] Figure 3The cytotoxicity of tetrahedron-near infrared quantum dot probes of different concentrations in Example 2 is shown;

[0026] Figure 4 The results of deep tumor tissue imaging using the tumor-targeting tetrahedron-near infrared quantum dot probe prepared in Example 3 are shown. DETAILED DESCRIPTION

[0027] The present invention will be further described below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not specified in the following examples are carried out according to conventional methods and conditions, or are selected according to the product specifications.

[0028] In the following specific implementation, the present invention mainly uses hydrophobic Ag2S quantum dots with near-infrared luminescence properties to construct tumor imaging probes, and uses the probes in tumor imaging to achieve targeted imaging of deep tumor tissues. The following examples specifically illustrate the implementation effects of the present invention.

[0029] Example 1 Preparation of DNA Tetrahedron-Near Infrared Quantum Dot Probe

[0030] Synthesis of DNA tetrahedron: Single-stranded DNA, S1-D, S2-D, S3-D, and S4-D accurately quantified by UV spectrophotometer were added to TM buffer at a stoichiometric ratio of 1:1:1:1, with a final concentration of each single strand of 1 μM. After thorough mixing, the mixture was placed in a PCR instrument for high-temperature annealing to obtain a tetrahedral structure modified with a hydrophobic cavity.

[0031] The sequences used for the DNA tetrahedron (SEQ ID NO. 1-4) are shown in Table 1 below:

[0032] Table 1

[0033] D is a modified hydrophobic alkyl chain with the following structural formula:

[0034] The hydrophobic Ag2S quantum dots with near-infrared luminescence properties were dissolved in dimethyl sulfoxide, and the Ag2S quantum dots and tetrahedrons were mixed at a molar ratio of 100:1 and ultrasonicated for 5 minutes to allow the hydrophobic Ag2S quantum dots to enter the hydrophobic cavity of the DNA tetrahedron by hydrophilic-hydrophobic interaction. Agarose gel electrophoresis was used to verify whether the quantum dots were successfully encapsulated. The preparation process of the tetrahedron-near-infrared quantum dot probe is as follows Figure 1 shown.

[0035] Results: Figure 2As shown, Ag2S quantum dots can be observed to have obvious fluorescent bands under a near-infrared gel irradiator. Further staining of the DNA in the gel with GelRed shows that the fluorescent bands are co-localized with the DNA bands, which indicates that the Ag2S quantum dots are indeed encapsulated in the hydrophobic cavity of the DNA tetrahedron, that is, this embodiment successfully prepares a DNA tetrahedron-near-infrared quantum dot probe.

[0036] Example 2 Biosafety of Tetrahedron-Near Infrared Quantum Dot Probes

[0037] Cell culture. H22 cells were purchased from the Cell Bank of the Chinese Academy of Sciences Type Culture Collection Committee. DMEM medium (containing 10% FBS, 100 units / mL penicillin, 100 μg / mL streptomycin, 2 mM glutamine) was used for culture in a constant temperature and humidity cell culture incubator at 37°C and 5% CO2.

[0038] Cytotoxicity. The cytotoxicity of the probe was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric method. H22 cells were plated at 3 × 10 3 The cells were seeded in a 24-well plate at a density of 10 cells and incubated for 12 hours to allow cell adhesion. Then different concentrations of tetrahedral-near infrared quantum dot probes were incubated with H22 cells for 12 hours, and then washed repeatedly with PBS to remove unbound probes and fresh cell culture medium was added to the plate wells. 500 μL of culture medium containing 0.5% MTT was added to each well. After 4 hours of incubation, 500 μL of triple lysis solution was added to each well and then allowed to stand at 37°C for 4 hours. The absorbance was measured at 570 nm using an ELISA reader.

[0039] result: Figure 3 The MTT analysis results showed that the tetrahedron-near-infrared quantum dot probe had little toxicity to cells even at the highest exposure dose of 1000nM.

[0040] Example 3 Targeted Imaging of Hepatocellular Carcinoma in Situ

[0041] Construction of nude mouse model of H22 orthotopic tumor: a large number of H22 cells were cultured. The culture of H22 cells was the same as in Example 2. After the mice (18-20 g nude mice, female, Shanghai Qianquan Biotechnology Co., Ltd.) were anesthetized and immobilized, the mice were fixed in a supine position on a mouse board, the limbs of the mice were fixed with tape, and a small cross-sectional incision of about 1 cm was made in the left abdominal cavity after disinfection with iodine tincture. The left lobe of the liver was gently pulled out with a cotton swab moistened with physiological saline to fully expose it. An appropriate amount of cell suspension 10 μL (1.5×10 6 mL -1) is slowly injected into the left lobe of the liver. After the injection is completed, the syringe is pulled out after staying in the left lobe of the liver for about 1-2 minutes. After a successful injection, press with a cotton swab to stop bleeding for about 1-2 minutes, put the liver back into the body, suture the incision layer by layer, apply antibiotics, place it in a warm box and pay attention to prevent infection. The mouse wakes up after about 30 minutes. The mouse is kept for 20 days to obtain an in situ liver cancer model in mice.

[0042] The RGD peptide was covalently modified on the tetrahedron-near-infrared quantum dot probe to obtain a tetrahedron-near-infrared quantum dot probe with the ability to actively target tumors. The probe solution of 1 μM (TM buffer solution, 100 μL) was injected into the tail vein, and the mice were anesthetized and immobilized. Under 808 nm laser irradiation, the near-infrared mouse live imaging results were obtained using an InGaAs CCD camera (Suzhou NIR-Optics Technology Co., Ltd., China).

[0043] Results: Imaging under 808nm laser irradiation, such as Figure 4 As shown, the experiment observed obvious near-infrared fluorescence signals at the liver cancer tumor site, indicating that the tetrahedron-near-infrared quantum dot probe can successfully image and detect in situ tumors of deep liver cancer.

[0044] The above is only a preferred embodiment of the present invention, and is not intended to limit the scope of the present invention. The above embodiment of the present invention can also be modified in various ways. That is, all simple, equivalent changes and modifications made according to the claims and the description of the present invention fall within the scope of protection of the claims of the present invention. The contents not described in detail in the present invention are all conventional technical contents.

Claims

1. A method for preparing a tumor-targeting tetrahedron-near infrared quantum dot probe, characterized in that: The following steps are involved: 1) Four DNA single strands are modified with hydrophobic alkyl chains respectively, and a DNA tetrahedral nanostructure with a hydrophobic cavity is prepared through a thermal annealing process; 2) Provide a hydrophobic quantum dot with near-infrared luminescence properties; 3) mixing the DNA tetrahedron and the hydrophobic quantum dots by oscillation or ultrasound, so that the hydrophobic quantum dots enter the hydrophobic cavity of the DNA tetrahedron, thereby preparing a tetrahedron-near infrared quantum dot probe; and 4) A tumor-targeting tetrahedron-near-infrared quantum dot probe can be prepared by covalently bonding the tumor-specific targeting molecule to the surface of the tetrahedron-near-infrared quantum dot probe through a chemical coupling reaction.

2. The preparation method according to claim 1, characterized in that: In step 1), the side length of the DNA tetrahedron is 20 base pairs, and the size of the DNA tetrahedron is about 6.8 nanometers.

3. The preparation method according to claim 1, characterized in that: In step 2), the hydrophobic quantum dots having near-infrared luminescence properties include: CdTe, PbS, PbSe, or Ag2S quantum dots.

4. The preparation method according to claim 3, characterized in that: In step 2), the size of the hydrophobic quantum dots having near-infrared luminescence properties does not exceed 5 nanometers.

5. The preparation method according to claim 1, characterized in that: In step 3), the hydrophobic quantum dots with near-infrared luminescent properties and DNA tetrahedrons are mixed in a molar ratio of (80-120):1 and then sonicated for 5 minutes to allow the hydrophobic quantum dots to enter the hydrophobic cavity of the DNA tetrahedron by hydrophilic-hydrophobic interaction, and agarose gel electrophoresis is used to verify whether the quantum dots are successfully encapsulated.

6. The preparation method according to claim 1, characterized in that: In step 4), the tumor-specific targeting molecule includes: an antibody, a polypeptide or a small molecule.

7. The preparation method according to claim 6, characterized in that: The antibodies include: Herceptin targeting human epidermal growth factor receptor 2, Rituximab targeting CD20 antigen, Cetuximab targeting epidermal growth factor receptor, or Bevacizumab targeting vascular endothelial growth factor, the polypeptides include: RGD polypeptide targeting integrin αvβ3 / β5, Bombesin polypeptide targeting gastrin releasing peptide receptor, or Folate polypeptide targeting folate receptor, and the small molecules include folic acid or glucose.

8. A tumor-targeting tetrahedron-near infrared quantum dot probe prepared according to the preparation method according to any one of claims 1 to 7, characterized in that: The tetrahedron-near-infrared quantum dot probe uses a DNA tetrahedron with a hydrophobic cavity to encapsulate quantum dots with near-infrared luminescence properties through hydrophilic-hydrophobic interactions, and covalently binds tumor-specific targeting molecules through a chemical coupling reaction.

9. Use of the tumor-targeting tetrahedron-near infrared quantum dot probe according to claim 8 in deep tissue tumor imaging, wherein the tumor imaging comprises: Tumor imaging for lung cancer, colorectal cancer, and liver cancer.

10. The use according to claim 9, characterized in that: The application The following steps are involved: S1: Construction of orthotopic liver cancer mouse model; S2: Provide a tetrahedron-near infrared quantum dot probe covalently modified with RGD peptide; S3: 1 μM of the tetrahedron-near-infrared quantum dot probe was injected into the tail vein, and after the mouse was anesthetized and immobilized, near-infrared live imaging of the mouse was performed under 808 nm laser irradiation.

Citation Information

Patent Citations

  • Near-infrared fluorescent tetrahedral probe as well as preparation method and application thereof

    CN117304920A